Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $17.29

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $17.29.

REPL has been the topic of several recent analyst reports. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC grew its holdings in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP lifted its position in shares of Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. State Street Corp lifted its position in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after purchasing an additional 238,747 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $12.64 on Friday. The stock has a fifty day moving average of $12.14 and a 200-day moving average of $10.32. The company has a market capitalization of $864.83 million, a PE ratio of -4.14 and a beta of 1.26. Replimune Group has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts anticipate that Replimune Group will post -2.91 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.